Get the Stockscreener App
6.65
4.23%
0.27
After Hours:
6.73
0.08
+1.20%
Coya Therapeutics Inc stock is traded at $6.65, with a volume of 71,858.
It is up +4.23% in the last 24 hours and down -25.78% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.38
Open:
$6.44
24h Volume:
71,858
Relative Volume:
0.93
Market Cap:
$106.59M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-5.0132
EPS:
-1.3265
Net Cash Flow:
$-11.39M
1W Performance:
+10.28%
1M Performance:
-25.78%
6M Performance:
-15.93%
1Y Performance:
+26.67%
1-Day Range:
$6.43
$6.79
1-Week Range:
$6.05
$6.91
52-Week Range:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.65 | 106.59M | 0 | -12.36M | -11.39M | -1.3265 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics to Present at Evercore HealthCONx Conference in December | COYA Stock News - StockTitan
Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN
Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India
Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya therapeutics CFO David Snyder buys $12,934 in stock - Investing.com
HC Wainwright Has Positive Forecast for COYA FY2024 Earnings - MarketBeat
Insider Buying: Coya Therapeutics Inc (COYA) Sees Purchase from Chief Medical Officer - GuruFocus.com
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results - MarketBeat
The Friday Biotech Perspective #32 - substack.com
Meet 5 of the fastest-growing scaleup companies in Houston - InnovationMap
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Q3 2024 Highlights and Progress - TipRanks
Coya Therapeutics board member resigns due to new job policy By Investing.com - Investing.com Canada
Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases - TipRanks
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - The Bakersfield Californian
Coya Therapeutics board member resigns due to new job policy - Investing.com India
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics reports promising Alzheimer's trial results By Investing.com - Investing.com South Africa
See the Impacts of Waco’s Walk to End Alzheimer’s - AOL
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya stock tumbles 23% on mixed results from Alzheimer's study - MSN
Coya stock tumbles 23% on mixed results from Alzheimer's study (NASDAQ:COYA) - Seeking Alpha
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth - Simply Wall St
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
Coya Therapeutics reports promising Alzheimer's trial results - Investing.com
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan
When (COYA) Moves Investors should Listen - Stock Traders Daily
Coya Therapeutics secures $10 million in private placement By Investing.com - Investing.com Australia
Coya Therapeutics Announces $10.0 Million Private Placement - citybiz
Coya Therapeutics Shares Rise 9% After $10 Million Private Placement - MarketWatch
Coya Therapeutics secures $10 million in private placement - Investing.com
Coya Therapeutics Announces $10M Private Placement to Advance Pipeline - TipRanks
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Coya Therapeutics Inc Stock (COYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):